

SANDERLING VENTURE PARTNERS IV CO INVESTMENT FUND LP
 Form 4
 March 26, 2008

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Sanderling Venture Partners IV, L.P.

2. Issuer Name and Ticker or Trading Symbol
 CARDIONET INC [BEAT]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
 400 SOUTH EL CAMINO
 REAL, SUITE 1200

3. Date of Earliest Transaction (Month/Day/Year)
 03/25/2008

____ Director
 ____ Officer (give title below)
 10% Owner
 ____ Other (specify below)

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 ____ Form filed by One Reporting Person
 Form filed by More than One Reporting Person

SAN MATEO, CA 94402

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)		
			Code	V	Amount	(A) or (D)	Price		
Common Stock	03/25/2008		C		48,909	A	<u>(1)</u> 53,604	I	See footnote <u>(2)</u>
Common Stock	03/25/2008		C		4,685	A	<u>(3)</u> 58,289	I	See footnote <u>(2)</u>
Common Stock	03/25/2008		C		327,630	A	<u>(3)</u> 327,630	I	See footnote <u>(4)</u>
Common Stock	03/25/2008		C		171,611	A	<u>(1)</u> 188,086	I	See footnote

Common Stock	03/25/2008	C	16,438	A	<u>(3)</u>	204,524	I	<u>(5)</u> See footnote <u>(5)</u>
Common Stock	03/25/2008	C	171,978	A	<u>(1)</u>	188,488	I	<u>(6)</u> See footnote <u>(6)</u>
Common Stock	03/25/2008	C	16,474	A	<u>(3)</u>	204,962	I	<u>(6)</u> See footnote <u>(6)</u>
Common Stock	03/25/2008	C	163,798	A	<u>(3)</u>	163,798	I	<u>(7)</u> See footnote <u>(7)</u>
Common Stock	03/25/2008	C	440,827	A	<u>(1)</u>	483,146	I	<u>(8)</u> See footnote <u>(8)</u>
Common Stock	03/25/2008	C	42,227	A	<u>(3)</u>	525,373	I	<u>(8)</u> See footnote <u>(8)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Convertible Preferred Stock	<u>(1)</u>	03/25/2008		C	97,819	<u>(1)</u>	<u>(1)</u>	Common Stock	48,909
Series C Convertible Preferred Stock	<u>(3)</u>	03/25/2008		C	9,370	<u>(3)</u>	<u>(3)</u>	Common Stock	4,685

Series C Convertible Preferred Stock	<u>(3)</u>	03/25/2008	C	655,261	<u>(3)</u>	<u>(3)</u>	Common Stock	327,630
Series B Convertible Preferred Stock	<u>(1)</u>	03/25/2008	C	343,223	<u>(1)</u>	<u>(1)</u>	Common Stock	171,611
Series C Convertible Preferred Stock	<u>(3)</u>	03/25/2008	C	32,877	<u>(3)</u>	<u>(3)</u>	Common Stock	16,438
Series B Convertible Preferred Stock	<u>(1)</u>	03/25/2008	C	343,957	<u>(1)</u>	<u>(1)</u>	Common Stock	171,978
Series C Convertible Preferred Stock	<u>(3)</u>	03/25/2008	C	32,948	<u>(3)</u>	<u>(3)</u>	Common Stock	16,474
Series C Convertible Preferred Stock	<u>(3)</u>	03/25/2008	C	327,596	<u>(3)</u>	<u>(3)</u>	Common Stock	163,798
Series B Convertible Preferred Stock	<u>(1)</u>	03/25/2008	C	881,655	<u>(1)</u>	<u>(1)</u>	Common Stock	440,827
Series C Convertible Preferred Stock	<u>(3)</u>	03/25/2008	C	84,454	<u>(3)</u>	<u>(3)</u>	Common Stock	42,227

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Sanderling Venture Partners IV, L.P. 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO, CA 94402		X		
Sanderling IV Limited Partnership 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO, CA 94402		X		

Sanderling (Feri Trust) Venture Partners IV, L.P.
 400 SOUTH EL CAMINO REAL X
 SUITE 1200
 SAN MATEO, CA 94402

SANDERLING IV BIOMEDICAL CO INVESTMENT FUND L P
 400 SOUTH EL CAMINO REAL X
 SUITE 1200
 SAN MATEO, CA 94402

SANDERLING IV BIOMEDICAL L P
 400 SOUTH EL CAMINO REAL X
 SUITE 1200
 SAN MATEO, CA 94402

SANDERLING VENTURE PARTNERS IV CO INVESTMENT FUND LP
 400 SOUTH EL CAMINO REAL X
 SUITE 1200
 SAN MATEO, CA 94402

Signatures

See Ex. 99.1 03/26/2008

 Signature of Date
 Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each 2 shares of Series B Convertible Preferred Stock converted into 1 share of the Issuer's common stock upon the closing of the initial public offering for no additional consideration and had no expiration date.
 By Sanderling [Feri Trust] Venture Partners IV, L.P. Fred Middleton, a member of the Issuer's board of directors is a general partner of Middleton-McNeil Investment Partners IV, L.P. the sole general partner of Sanderling [Feri Trust] Venture Partners IV, L.P. and has voting and investment power over the shares held by Sanderling [Feri Trust] Venture Partners IV, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- (2) Each 2 shares of Series C Convertible Preferred Stock converted into 1 share of the Issuer's common stock upon the closing of the initial public offering for no additional consideration and had no expiration date.
 By Sanderling IV Biomedical Co-Investment Fund, L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates IV, LLC the sole general partner of Sanderling IV Biomedical Co-Investment Fund, L.P. and has voting and investment power over the shares held by Sanderling IV Biomedical Co-Investment Fund, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- (3) By Sanderling IV Biomedical, L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates IV, LLC the sole general partner of Sanderling IV Biomedical, L.P. and has voting and investment power over the shares held by Sanderling IV Biomedical, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- (4) By Sanderling IV Limited Partnership. Fred Middleton, a member of the Issuer's board of directors is a general partner of Middleton-McNeil IV, L.P. the sole general partner of Sanderling IV Limited Partnership and has voting and investment power over the shares held by Sanderling IV Limited Partnership. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- (5) By Sanderling Venture Partners IV Co-Investment Fund, L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates IV, LLC the sole general partner of Sanderling Venture Partners IV Co-Investment Fund, L.P. and has voting and investment power over the shares held by Sanderling Venture Partners IV Co-Investment Fund, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- (6)
- (7)

Edgar Filing: SANDERLING VENTURE PARTNERS IV CO INVESTMENT FUND LP - Form 4

- (8) By Sanderling Venture Partners IV, L.P. Fred Middleton, a member of the Issuer's board of directors is a general partner of Middleton-McNeil Associates IV, L.P. the sole general partner of Sanderling Venture Partners IV, L.P. and has voting and investment power over the shares held by Sanderling Venture Partners IV, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Remarks:

Exhibit 24.1 Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.